This study, called SCORE, is collecting blood and tissue samples from people with certain solid cancers, including breast, lung, and pancreatic cancer. The goal is to help Natera evaluate how well their molecular residual disease (MRD) tests work. These tests look for tiny amounts of cancer DNA (circulating tumor DNA or ctDNA) in the blood, which could help doctors detect if cancer is coming back or how well treatment is working. You can join if you are 18 or older and have an untreated primary solid tumor from the specified cancer types. The study aims to collect samples and data for up to eight years to understand the long-term performance of these tests. No individual test results will be shared with you or your doctor.

Study design

This is an observational study planning to enroll 9600 participants across multiple sites. It is not testing a specific intervention but rather collecting samples and data.

What's involved

You would provide blood samples periodically, approximately every six weeks for up to two years after surgery or primary treatment. Residual tissue samples from standard-of-care procedures will also be collected. You will have data-only follow-up visits at one and five years after the final blood collection.

Compensation

Not stated in the trial record.

Follow-up

Participants may be followed for up to eight years, with data-only follow-up visits at one and five years after the final blood collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.